partners in care to improve quality of life abboud bejjani vice president abbvie biopharmaceutical...

Partners in care to Improve Quality of Life

Abboud BejjaniVice President AbbVie Biopharmaceutical

Cairo March 13/2014

People Passion Possibilities

Vice PresidentMiddle East, Africa & Pakistan

Who I am?

Degree…

15 Years!Consulting


A leading global biopharmaceutical company one year old, but carrying 120 years history in research.AbbVie aspires to contribute to Healthcare Sustainability via Innovative Medicines and New Healthcare Solutions.

(Chicago Based company)

AbbVie… Who We are?


AbbVie Way!

Leading biopharmaceutical company in the life sciences industry that fosters pharma innovation & competitiveness

a long-term, reliable Partner and a key contributor to the economy and healthcare sustainability

Responsibly active member of the community


AbbViePart of the Innovative Biopharmaceutical Industry

The innovative biopharmaceutical industry represents global leading pharmaceutical research and biotechnology companies

Our companies are devoted to discovering new medicines that allow patients to live longer, healthier, and more productive lives

In 2009, the biopharmaceutical sector invested approximately $65.3 billion in research and development


Biopharmaceutical Companies’Investment in R&D Increasing Steadily

$47.9$50.3

65.2

$47.60$51.80

$63.2

$56.1

$37.0$39.9

$34.5

$29.8

$22.7$19.0

$15.2

$31.0

$26.0

$21.0$16.9

$43.4

$0

$10

$20

$30

$40

$50

$60

$70

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008(est)

Exp

end

itu

res

(Bil

lio

ns

of

Do

llar

s)

Entire Pharma Sector PhRMA Member Companies' R&D Expenditures

Total Biopharmaceutical Company R&D and PhRMA Member R&D: 1995–20081

Sources: 1Burrill & Company, analysis for PhRMA, 2005–2009; Pharmaceutical Research and Manufacturers of America, PhRMA Annual Member Survey (Washington, DC: PhRMA, 1981-2009); 2CBO, Research and Development in the Pharmaceutical Industry, 2006.

The pharmaceutical industry is one of the most research-intensive industries in the United States. Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average U.S. manufacturing firm.2

— Congressional Budget Office

““


AbbVie Leading Therapeutical Areas & Research Focus

1. Immunology • Rheumatoid Arthritis• Ankylosing Spondylitis • Psoriasis• Crohn’s Disease

2. Neonatology (preterm babies)

3. Anesthesia

4. Antiviral (HIV/HCV)

5. Renal Disease

6. Central Nervous System

7. Oncology


Can we Partner ?AbbVie & The Arab WorldLong Term Relation Ship

Over 60 years of PartnerShip!

Partners in care to Improve Quality of Life


Health Authorities’ Objectives

Objective How Consequence

By Improving Longevity and Quality of Life

By Widening AccessTo Care

Manage rising Healthcare costs

Higher Quality Care


How we can help?

Technology and knowledge transfer

Improve patient access to innovative medicines and as results improve patient outcomes

Improve efficiency of healthcare delivery

Anticipate in boosting the economy by local investments

Create high quality jobs



Prescription medicines play a major role in saving and improving lives

Over the last 25 years, prescription medicines have significantly reduced deaths from major diseases such as heart disease, several cancers, and HIV /AIDS

Improved the quality of lives of people suffering from conditions such as arthritis disease. Currently we are talking about full remission from Many Immune Diseases such as Crohn’s, Rheumatoid Arthritis, Psoriasis, Parkinson, needless to mention the prematurity solutions for babies…etc…

Recent advances include a new generation of personalized medicines, treatment for some rare diseases and cure for infections like Hepatitis C.


Major Advances in Treatment and Prevention

Since 1980 life expectancy for cancer patients has increased by 3 years. Research finds that medicines alone account for 50-60% of survival increases.

Thanks in part to new medicines, heart failure and heart attack deaths fell by 45% in just the last decade.

Within three years of introduction of the first antiretroviral treatments, HIV/AIDS deaths dropped by nearly 70%.

“The rapid increases that have been observed in drug-related R&D spending

have been accompanied by major therapeutic gains in available drug

treatments.” CBO, 2006

12


HIV/AIDS: Decline in Death rates


U.S. Life Expectancy 1950-2007


How we can help?







Improving Efficiency of Healthcare Delivery

Efficient management of Non Communicable Diseases through :

• Health education

• Disease management programs

• Patient screening programs

Eradication of communicable diseases

• Early introduction of innovative therapeutic options

Continuous medical education of HCP

Training of healthcare professionals


Some Real Life Examples of Health Education–IMID Congress

IMID – Immune Mediated Inflammatory Disorders Congress

5% -7% MEA population is afflicted

Treated and managed by multi-specialists like Rheumatologists, Dermatologists, Gastroenterologists, Ophthalmologists and Internists who have little time and opportunity to communicate with each other.

IMID Congress created a multispecialty platform to bring these specialists together to discuss the latest developments and research to achieve improved patient outcomes. Result: Increased referrals of patients across the specialties that facilitates better co-management of patients.











Public Awareness


AbbVie partnered with GENERAL Electric to support continuous education of Rheumatologists who were interested in learning ultrasound of the joints. This education was the first of its kind in the MEA and helped to improve the standard of care of the RA patients and support the physician in diagnosis and monitoring of the disease.

Result: Rheumatologists started using US in practice and ultrasound became increasingly recognized as a standard tool for diagnosing and treating the aggressive disease early.

Some Real Life Examples of what we did –Academy of Imaging











Public Awareness


Some Real Life Examples of what we did –Patient Support Program

Patient Support Specialists (trained physicians and pharmacists by qualification) educate patients on disease understanding and elevate awareness on possible detrimental outcomes if left untreated. In addition:• Organize patients’ days whereby consultants are invited to educate patients •Advise patients to follow up with Physiotherapists•Organize meetings of patients with Nutritionists to learn about optimal diet regime.•Facilitate appointment with Psychiatrists for the depressed Ps patients if needed

The program is endorsed by MOH and Health Authorities

Received endorsement of the Her Royal Highness Princess Oraib Al Saud (daughter of HH Saudi King) to endorse a valuable program aimed to raise prematurity awareness and to call for action to set the healthcare standards of Neonatology in Saudi.The program is supported by many other corporate partners.


How we can help?







Health Authorities’ Objectives

Objective How Consequence

Improve Longevity and Quality of Life

Wider AccessTo Care

Manage rising Healthcare costs

Higher Quality Care


How we can help?


PPP: Elements of Success !

Trust

Transparency

Open Dialogue


What is required from our side!

Trust

Transparency

Open DialogueMore discussion Don’t be afraid!

Show what we do

Better Understanding of your challenges


What we like you to do!

Trust

Transparency

Open DialogueOpen hears for Pharma Economics Discussion

Pharma As a Cost component of Health Bill

Better Understanding of our challenges


Industry Concern : Valuable But Vulnerable

29

Limitless

Opportunities

Growing

Cha

lleng

e

People Passion Possibilities30

DO YOU KNOW??Developing a new medicine is lengthy, risky, and costly.

New drug development takes an average of 10–15 years, and costs approx. US $1.3 billion.

INDEFINITE

Drug Discovery Preclinical Clinical Trials FDA Review Scale-Up to Mfg. Post-MarketingSurveillance

ONE FDA-APPROVED

DRUG

0.5 – 2 YEARS6 – 7 YEARS3 – 6 YEARS

NUMBER OF VOLUNTEERS

PHASE 1

PHASE 2

PHASE 3

5250~ 5,000 – 10,000

COMPOUNDS

PR

E-D

ISC

OV

ER

Y

20–100 100–500 1,000–5,000

IND

SU

BM

ITT

ED

ND

A S

UB

MIT

TE

D

Sources: Drug Discovery and Development: Understanding the R&D Process, www.innovation.org


Do you know??Cost to Develop One New Drug

$1.3B

$800M

$300M

$100M

$0.0

$0.2

$0.4

$0.6

$0.8

$1.0

$1.2

$1.4

1979 1991 2000 2005

31

Bil

lio

ns


Successfully Approved Commercial Medecines



Trust

Transparency




People Passion Possibilities34

Medicines can Result in Extraordinary Savings for Patients and Health Systems

• In the U.S., for example, each prescription saves US $57 in avoidable hospital costs.

• Diabetes: $1 more spent on diabetes medicines = US $7.10 less spent on other services.

• High Blood Pressure: In 2002, antihypertensives prevented 833,000 stroke and heart attack hospitalizations, saving US $16.5 billion in medical costs.

• Asthma: A 10% increase in adherence to asthma medicines in elderly patients leads to a 5% decrease in total annual medical spending.

Medicines can reduce health costs by preventing and managing disease

Sources: Sources: B.C. Stuart, et al. ”Assessing the Impact of Drug Use on Hospital Costs.”Health Services Research, February 2009; M.C. Sokol, K.A. McGuigan, R.R. Verbrugge, R.S. Epstein, “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost,” Medical Care, 43 (2005): 6, 521-530; D. Cutler, et al., “The Value of Antihypertensive Drugs: A Perspective on Medical Innovation,” Health Affairs, January/February, 2007; B. Briesacher, et al. “Consequences of Poor Compliance with Biphosphonates,” Bone, 2007.R. Balkrishnan, et al., “Self-Reported Health Status, Prophylactic Medication Use, and Healthcare Costs in Older Adults with Asthma,: Journal of the American Geriatric Society, 2002.



Trust

Transparency





Medicines and Health Spending Growth


We need Common understanding!

Trust

Transparency

Open Dialogue

Common Interest and Better understanding of each other needs


Improving Patients’ Health and Quality of Life

“New drugs allow children with rheumatoid arthritis to walk and to go to school. New drugs shrink cancerous tumors and they control the advance of HIV. They prevent or halt heart disease, slow the progression of multiple sclerosis, and cure infectious diseases.” 13

—Mark B. McClellan, M.D., Ph.D., Then-FDA Commissioner,September 2003


YES WE ARE PARTNERS!!!

Partners in care to Improve

Quality of Life

THANK YOU

partners in care to improve quality of life abboud bejjani vice president abbvie biopharmaceutical...

Documents

quality of life slide

development slide

innovative medicines

community slide

oncology slide

consulting slide

new medicines

high quality jobs slide